en
Scientific article
English

Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance

Published inClinical nuclear medicine, vol. 37, no. 10, p. 960-964
Publication date2012
Abstract

This study aimed to evaluate the efficacy and toxicity of radioimmunotherapy (RIT) in recurrent lymphoma after hematopoietic stem cell transplantation (HSCT).

Keywords
  • Adult
  • Aged
  • Antibodies, Monoclonal/adverse effects
  • Female
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma/radiotherapy/surgery
  • Male
  • Middle Aged
  • Radioimmunotherapy/adverse effects
  • Recurrence
  • Retrospective Studies
  • Time Factors
  • Transplantation, Homologous/adverse effects
Citation (ISO format)
BUCHEGGER, Franz et al. Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance. In: Clinical nuclear medicine, 2012, vol. 37, n° 10, p. 960–964. doi: 10.1097/RLU.0b013e318251e3af
Identifiers
ISSN of the journal0363-9762
426views
0downloads

Technical informations

Creation11/27/2015 12:36:00 PM
First validation11/27/2015 12:36:00 PM
Update time03/14/2023 11:58:33 PM
Status update03/14/2023 11:58:33 PM
Last indexation01/16/2024 7:50:10 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack